Close
ACHEMA MIDDLE EAST 2026

Canada authorizes Pfizer COVID vaccine booster for adults

AI Summary

Health Canada has authorized the use of the Pfizer-BioNTech Comirnaty COVID-19 vaccine as a booster shot. A COVID-19 booster shot is an extra dose of the vaccine given after completion of the primary vaccine series. The booster shot is designed to help people maintain their protection against COVID-19 over time.

Health Canada received Pfizer’s submission to approve a booster on October 1, 2021. After a thorough, independent review of the evidence, Health Canada has determined that the Comirnaty COVID-19 vaccine booster shot meets the Department’s stringent safety, efficacy and quality requirements.

The booster is authorized for adults 18 years of age and older, to be used at least six months after an individual has completed their primary vaccine series. The Comirnaty COVID-19 booster is a full dose of the regular vaccine (30 mcg).

Evidence continues to show that being fully vaccinated provides strong protection against serious illness, hospitalization and death from COVID-19, including against the Delta variants.

People in Canada should consult their local public health guidance, informed by the National Advisory Committee on Immunization, for details on which individuals or groups of people are recommended to receive a booster dose at this time.

The pharmaceutical industry rarely announces its most significant shifts loudly. The signals are there — if you know where to look.

The Pharma Advancement briefing is how the sector’s most informed professionals stay ahead of those signals — covering drug development, regulatory affairs, manufacturing, and market access across every major region.

  • The stories pharmaceutical professionals will be discussing tomorrow, in your inbox today
  • Analysis that goes beyond the headline — written for readers who already understand the industry
  • The briefing that the sector’s most informed professionals open first

SUBSCRIBE OUR NEWSLETTER

WHITE PAPERS

RELATED ARTICLES